Evidence map›Paper›PMID 25736597›Full record

ArticleScientific reports2015

MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.

Mingrong Lü, Keshuo Ding, Guofeng Zhang, Mianmian Yin, Guidong Yao, Hui Tian, Jie Lian, Lin Liu, Meng Liang, Tao Zhu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Estrogen-related Receptor Signaling in Skeletal Muscle Fitness.International journal of sports medicine · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Mingrong Lü1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China.
Keshuo Ding1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China [3] Department of Pathology, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Guofeng ZhangDepartment of General Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, People's Republic of China.
Mianmian Yin1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China.
Guidong YaoReproductive Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, People's Republic of China.
Hui Tian1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China.
Jie Lian1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China.
Lin Liu1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China.
Meng Liang1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China.
Tao Zhu1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China.
Fei Sun1] Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, People's Republic of China [2] Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, People's Republic of China.
University of Science and Technology of China · CNHefei National Center for Physical Sciences at Nanoscale · CNFirst Affiliated Hospital of Zhengzhou University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tamoxifen represents a major adjuvant therapy to those patients with estrogen receptor-alpha positive breast cancer. However, tamoxifen resistance occurs quite often, either de novo or acquired during treatment. To investigate the role of miR-320a in the development of resistance to tamoxifen, we established tamoxifen-resistant (TamR) models by continually exposing MCF-7 or T47D breast cancer cells to tamoxifen, and identified microRNA(miRNA)-320a as a down-regulated miRNA in tamoxifen resistant cells. Re-expression of miR-320a was sufficient to sensitize TamR cells to tamoxifen by targeting cAMP-regulated phosphoprotein (ARPP-19) and estrogen-related receptor gamma (ERRγ) as well as their downstream effectors, c-Myc and Cyclin D1. Furthermore, progesterone (P4) promoted the expression of miR-320a by repressing c-Myc expression, while estrogen (E2) exerted the opposite effect. These results suggest the potential therapeutic approach for tamoxifen-resistant breast cancer by restorating miR-320a expression or depleting ARPP-19/ERRγ expression.

Indexed as

AnimalsAntineoplastic Agents, HormonalBreast NeoplasmsCell Line, TumorCell SurvivalDrug Resistance, NeoplasmEstrogensFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMCF-7 CellsMice, NudeMicroRNAsPhosphoproteinsProgesteroneAntineoplastic Agents, Hormonalcyclic AMP-regulated phosphoprotein 19ESRRG protein, humanEstrogensMicroRNAsMIRN320 microRNA, humanPhosphoproteinsProgesteroneProto-Oncogene Proteins c-mycReceptors, EstrogenTamoxifen

Identifiers

PMID25736597
PMCPMC4348640
OpenAlexW2017735822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.